Posts - CLL Support | HealthUnlocked

CLL Support

22,514 members • 38,671 posts

Treatments & trials posts

Sort posts by:

Encouraging phase 1 trial results for GLPG5201, a CAR T-cell therapy

Introducing the Phase I EUPLAGIA-1 study (EudraCT 2021-003815-25), which investigated GLPG5201, a CD19 CAR T-cell therapy, in relapsed/refractory (R/R)...

Introducing the Phase I EUPLAGIA-1 study (EudraCT 2021-003815-25), which investi...

bennevisplace

•7 days ago

4 Replies

Majic trial arm "A"

For the Majic trail, arm "A", I would like to know if anyone has completed the first 15 cycles of Acalabrutinib and Venetoclax. Has your bone marrow testing...

For the Majic trail, arm "A", I would like to know if anyone has completed the f...

JDG45

•1 month ago

12 Replies

A potential game-changer for CAR T cell therapy: mutations in cancer engineered to beat cancer

CAR T therapy has been successful in some acute blood cancers. Response rates, however, are considerably lower in CLL and solid tumours, with T cell exhaustion...

CAR T therapy has been successful in some acute blood cancers. Response rates, h...

bennevisplace

•3 months ago

4 Replies

Want to take advantage of all our features? Just log in!

Flair Trial Completed

It’s official I have completed 6 years of taking part in the I. & R Arm of the Flair Trial today . I started on 28th January 2018 and I took my last dose of...

It’s official I have completed 6 years of taking part in the I. & R Arm of the...

Sanphil

•3 months ago

8 Replies

Current SUPERNOVA Clinical Trial for Reformulated EVUSHELD for preventing COVID-19 infection for immune-impaired individuals

A Phase II sub-study of SUPERNOVA clinical trial (2023) is currently operating to test the efficacy and safety of AZD3152 as a component of a reformulated...

A Phase II sub-study of SUPERNOVA clinical trial (2023) is currently operating t...

Classicaljazz

•3 months ago

5 Replies

How you can help make ibrutinib plus venetoclax fixed duration therapy a reality for Australians with previously untreated CLL

In Australia, no new medicine can be listed on the Pharmaceutical Benefits Scheme (PBS) unless it has first been recommended by the Pharmaceutical Benefits...

In Australia, no new medicine can be listed on the Pharmaceutical Benefits Schem...

CLLerinOz

Administrator•5 months ago

6 Replies

Drugs.com FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed (CAR) T cell Immunotherapies

https://newsletters.drugs.com/l/HXdBAPWpNu8924jmwPHb3VvA/LQCEtlvhvlnyLNQoIP4Gfw/jLVV3dtGc2BI8hLRqrMq892g "Although the overall benefits of these products...

https://newsletters.drugs.com/l/HXdBAPWpNu8924jmwPHb3VvA/LQCEtlvhvlnyLNQoIP4Gfw/...

JerrysGirl3

•5 months ago

2 Replies

A new kid on the block? Nemtabrutinib

Hi All, There is a new targeted drug in Clinical Trials that may offer a new treatment option for us CLLers—Nemtabrutinib. For the entire article on this...

Hi All, There is a new targeted drug in Clinical Trials that may offer a new tr...

Varney

•6 months ago

18 Replies

Efficacy and safety of new‑generation BTKis (primarily acalabrutinib and zanubrutinib) in CLL/SLL: a systematic review and meta‑analysis

The meta-analysis of 20 studies on CLL/SLL patients treated with new-generation BTKis was based on papers selected from "A comprehensive search on PubMed,...

The meta-analysis of 20 studies on CLL/SLL patients treated with new-generation ...

AussieNeil

Administrator•6 months ago

17 Replies

Venetoclax has been added to the Pharmaceutical Benefits Scheme in Australia for use as a retreatment for CLL/SLL

In more good news, today the Pharmaceutical Benefits Scheme (PBS) in Australia added venetoclax to its listings for the retreatment of CLL/SLL in those whose...

In more good news, today the Pharmaceutical Benefits Scheme (PBS) in Australia a...

CLLerinOz

Administrator•8 months ago

8 Replies

Zanubrutinib has been listed on the Pharmaceutical Benefits Scheme in Australia as a first line treatment for CLL/SLL

Australia's Pharmaceutical Benefits Scheme (PBS) today added Zanubrutinib as a first line therapy for the treatment of CLL/SLL. As well as being available...

Australia's Pharmaceutical Benefits Scheme (PBS) today added Zanubrutinib as a f...

CLLerinOz

Administrator•8 months ago

4 Replies

Largest real world study of acalabrutinib and ibrutinib over 3 years, shows acalabrutinib has improved discontinuation rates

We've had several posts in the last 24 hours about the U.S. government's plans to negotiate a price for ibrutinib. I mentioned...

We've had several posts in the last 24 hours about the U.S. government's plans t...

AussieNeil

Administrator•8 months ago

2 Replies

Starting therapy 5 yrs post CAR-T with another immunotherapy trial, now epcoritamab

Making my exercise "rounds" at the hospital It was a nice long run and far exceeded the average duration of response to CAR-T in CLL, but as we all...

Making my exercise "rounds" at the hospital It was a nice long run and far exce...

bkoffman

CLL CURE Hero•8 months ago

63 Replies

Now showing on Vjhemonc CLL channel, Epcoritamab for Richter's, identifying high risk CLL, Pirtobrutinib Genomic Evolution, HOVON 141/VISION

The latest videos on the CLL channel https://www.vjhemonc.com/subject/chronic-lymphocytic-leukemia/#latest-videos. complement some of the recent posts on new...

The latest videos on the CLL channel https://www.vjhemonc.com/subject/chronic-ly...

AussieNeil

Administrator•11 months ago

9 Replies

Tumor Lysis Syndrome: What ( CLL ) Patients Need to Know (Leukemia and Lymphoma Society podcast)

Many of us are aware of the risk of tumor lysis syndrome (TLS) when we commence treatment, particularly with venetoclax and that the purpose of the venetoclax...

Many of us are aware of the risk of tumor lysis syndrome (TLS) when we commence ...

AussieNeil

Administrator•1 year ago

6 Replies

Brother about to start treatment, advice please

My brother was diagnosed with CLL just over 2 years ago. He’s about to start treatment with obinutuzumab and venetoclax. He’s on a few meds for blood pressure...

My brother was diagnosed with CLL just over 2 years ago. He’s about to start tre...

EricSun

•1 year ago

4 Replies

Venetoclax Consolidation Achieves Durable Off-Treatment Remissions in Patient with High Risk CLL Who Have Been on Ibrutinib More Than a Year

This is something that some of our USA members have discussed with their doctors and it looks like the logic is correct. "Patients (pts) receiving...

This is something that some of our USA members have discussed with their doctors...

Jm954

Administrator•1 year ago

4 Replies

1.5 million atrial fibrillation cases may be undiagnosed in US (prevalence estimate of 11%)

An analysis of five U.S. medical claims databases suggests as many as 23% of 5.6 million to 6.6 million presumptive atrial fibrillation cases are...

An analysis of five U.S. medical claims databases suggests as many as 23% of 5.6...

AussieNeil

Administrator•1 year ago

6 Replies

Fascinating: Development of Venetoclax

For a few years, I've taken a breather from HU while focusing on full life rather than my CLL. I'm stepping up to post a new podcast from Dana Farber Hospital,...

For a few years, I've taken a breather from HU while focusing on full life rathe...

starsafta

•1 year ago

7 Replies

Interesting read from CLL Society - High-Titer Convalescent Plasma for an Immunocompromised Patient with Active COVID-19

https://cllsociety.org/2023/01/high-titer-covid-19-convalescent-plasma-as-a-treatment-option-for-those-who-are-immunocompromised-after-becoming-infected-with-co

https://cllsociety.org/2023/01/high-titer-covid-19-convalescent-plasma-as-a-trea...

Floydpup

•1 year ago

1 Reply

vision change after taking Calquence / acalabrutinib for CLL

my eyesight gets really blurry after I take my medicine

Helma77

•1 year ago

5 Replies

Chronic lymphocytic leukemia treatment algorithm 2022

This 29 November 2022 review article published in the Blood Cancer Journal presents an up-to-date treatment algorithm for CLL....

This 29 November 2022 review article published in the Blood Cancer Journal prese...

CLLerinOz

Administrator•1 year ago

17 Replies

Treatment-naive or relapsed CLL patients will soon have zanubrutinib/Brukinsa as a treatment option in the EU

The EC approval is based on positive results from two Phase 3 clinical trials: SEQUOIA (NCT03336333), in patients with previously untreated CLL, and ALPINE...

The EC approval is based on positive results from two Phase 3 clinical trials: S...

AussieNeil

Administrator•1 year ago

18 Replies

Any recent experiences of AIHA developing in progressive CLL - particularly in those treated with or awaiting Venetoclax treatment?

Hi all. Well, 2nd line treatment day one came yesterday, and I dutifully scrubbed up and turned up at the hospital for 0830 to start my planned Venetoclax ramp...

Hi all. Well, 2nd line treatment day one came yesterday, and I dutifully scrubbe...

jibs60

•1 year ago

25 Replies

start of treatment

I am diagnosed with CLL in 2003 and has been on wait and watch. Del 17 but mutated IGHV. WBC count and platlets are stable for last 6 months with around 1...

I am diagnosed with CLL in 2003 and has been on wait and watch. Del 17 but mutat...

Ashwas

•1 year ago

9 Replies

The Dragon is Rearing It's Ugly Head

Here is a link to my blog: https://drlaverne.blogspot.com/2022/07/the-dragon-is-rearing-its-ugly-head.html Please let me know if you are able to subscribe. I...

Here is a link to my blog: https://drlaverne.blogspot.com/2022/07/the-dragon-is...

DrLV

•2 years ago

10 Replies

PI3K inhibitors (idelalisib,copanlisib, duvelisib, parsaclisib, umbralisib, zandelisib, ACP-319) in CLL: where do we go from here?

While we have never been as spoiled for treatment choice as we are now, PI3K inhibitor safety is being very closely monitored by the FDA. So, it's timely...

While we have never been as spoiled for treatment choice as we are now, PI3K inh...

CLLerinOz

Administrator•2 years ago

6 Replies

Attention Those Taking Ibrutinib & BTK Inhibitors:Second Cancer Incidence in CLL Patients Receiving BTK Inhibitors

The publication examines the relationship between the use of ibrutinib and acalabrutinib with the incidence of second primary cancers. There are data on risk...

The publication examines the relationship between the use of ibrutinib and acala...

Yalokin

•2 years ago

28 Replies

Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase 2 Study of an MRD-driven Approach

Purpose: Ibrutinib has transformed the management of CLL, though its use is limited by toxicity and resistance. In this study, we utilized an...

Purpose: Ibrutinib has transformed the management of CLL, though its use is limi...

AussieNeil

Administrator•2 years ago

2 Replies

Evusheld and risk

Hi. I read that there is little evidence of the effectiveness of Evusheld and there is a degree of risk for side effects such as cardiac incidents. I have...

Hi. I read that there is little evidence of the effectiveness of Evusheld and th...

naddude

•2 years ago

14 Replies

Write a post or ask a question

Posts - CLL Support | HealthUnlocked

CLL Support

Treatments & trials posts

Encouraging phase 1 trial results for GLPG5201, a CAR T-cell therapy

Majic trial arm "A"

A potential game-changer for CAR T cell therapy: mutations in cancer engineered to beat cancer

Flair Trial Completed

Current SUPERNOVA Clinical Trial for Reformulated EVUSHELD for preventing COVID-19 infection for immune-impaired individuals

How you can help make ibrutinib plus venetoclax fixed duration therapy a reality for Australians with previously untreated CLL

Drugs.com FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed (CAR) T cell Immunotherapies

A new kid on the block? Nemtabrutinib

Efficacy and safety of new‑generation BTKis (primarily acalabrutinib and zanubrutinib) in CLL/SLL: a systematic review and meta‑analysis

Venetoclax has been added to the Pharmaceutical Benefits Scheme in Australia for use as a retreatment for CLL/SLL

Zanubrutinib has been listed on the Pharmaceutical Benefits Scheme in Australia as a first line treatment for CLL/SLL

Largest real world study of acalabrutinib and ibrutinib over 3 years, shows acalabrutinib has improved discontinuation rates

Starting therapy 5 yrs post CAR-T with another immunotherapy trial, now epcoritamab

Now showing on Vjhemonc CLL channel, Epcoritamab for Richter's, identifying high risk CLL, Pirtobrutinib Genomic Evolution, HOVON 141/VISION

Tumor Lysis Syndrome: What ( CLL ) Patients Need to Know (Leukemia and Lymphoma Society podcast)

Brother about to start treatment, advice please

Venetoclax Consolidation Achieves Durable Off-Treatment Remissions in Patient with High Risk CLL Who Have Been on Ibrutinib More Than a Year

1.5 million atrial fibrillation cases may be undiagnosed in US (prevalence estimate of 11%)

Fascinating: Development of Venetoclax

Interesting read from CLL Society - High-Titer Convalescent Plasma for an Immunocompromised Patient with Active COVID-19

vision change after taking Calquence / acalabrutinib for CLL

Chronic lymphocytic leukemia treatment algorithm 2022

Treatment-naive or relapsed CLL patients will soon have zanubrutinib/Brukinsa as a treatment option in the EU

Any recent experiences of AIHA developing in progressive CLL - particularly in those treated with or awaiting Venetoclax treatment?

start of treatment

The Dragon is Rearing It's Ugly Head

PI3K inhibitors (idelalisib,copanlisib, duvelisib, parsaclisib, umbralisib, zandelisib, ACP-319) in CLL: where do we go from here?

Attention Those Taking Ibrutinib & BTK Inhibitors:Second Cancer Incidence in CLL Patients Receiving BTK Inhibitors

Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase 2 Study of an MRD-driven Approach

Evusheld and risk

Search posts

Pinned Posts

Latest poll

Part 2 of How well do you know HealthUnlocked's features? Rate yourself on this multichoice poll. Answers later or you can check Help!

Topics

Archive